Premium
Rhodium(II) Proximity‐Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti‐Leukemia Activity
Author(s) -
Minus Matthew B.,
Liu Wei,
Vohidov Farrukh,
Kasembeli Moses M.,
Long Xin,
Krueger Michael J.,
Stevens Alexandra,
Kolosov Mikhail I.,
Tweardy David J.,
Sison Edward Allan R.,
Redell Michele S.,
Ball Zachary T.
Publication year - 2015
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.201506889
Subject(s) - myeloid leukemia , stat3 , stat protein , leukemia , cancer research , chemistry , activator (genetics) , in vivo , transcription factor , downregulation and upregulation , biology , apoptosis , immunology , biochemistry , gene , genetics
Nearly 40 % of children with acute myeloid leukemia (AML) suffer relapse arising from chemoresistance, often involving upregulation of the oncoprotein STAT3 (signal transducer and activator of transcription 3). Herein, rhodium(II)‐catalyzed, proximity‐driven modification identifies the STAT3 coiled‐coil domain (CCD) as a novel ligand‐binding site, and we describe a new naphthalene sulfonamide inhibitor that targets the CCD, blocks STAT3 function, and halts its disease‐promoting effects in vitro, in tumor growth models, and in a leukemia mouse model, validating this new therapeutic target for resistant AML.